Skip to main content

Table 4 Cox model of association of baseline characteristics with overall survival

From: Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Characteristic Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age, years
  ≥ 75 vs < 75 0.62 (0.39–0.98) 0.04 0.55 (0.35–0.87) 0.01
Gender
 Male vs female 1.18 (0.82–1.71) 0.36  
Metastatic site, yes vs no
 Bone 1.35 (0.99–1.84) 0.06  
 Liver 1.05 (0.76–1.46) 0.75  
 CNS 1.39 (0.84–2.31) 0.20  
Number of prior therapies
  > 1 vs 1 1.80 (1.15–2.87) 0.01  
First line
 Sunitinib vs pazopanib 1.24 (0.84–1.84) 0.28   
Prior everolimus
 Yes vs no 1.30 (0.95–1.76) 0.10   
Drug-related toxicity (drAEs)
 Yes vs no 0.64 (0.46–0.91) 0.01  
Ir toxicity (irAEs)
 Yes vs no 0.48 (0.30–0.78) 0.003 0.57 (0.35–0.93) 0.02
Number of Nivolumab doses
  > 4 vs ≤4 0.11 (0.08–0.15) < 0.0001 0.11 (0.08–0.15) < 0.0001
  1. Abbreviations: CI confidence interval, HR hazard ratio, CNS central nervous system